DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Micardis®. Observational Study in Patients With Essential Hypertension

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Low dose of Telmisartan, once daily (Drug); High dose of Telmisartan, once daily (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

This study is designed to supplement, under conditions of usual clinical practice, the data on the efficacy and safety of Micardis« collected during the clinical studies.

Clinical Details

Official title: Micardis«. Observational Study

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Changes in systolic and diastolic blood pressure

Percentage of patients with dose titration to 80 mg

Number of patients with adverse events

Global evaluation of treatment compliance by investigator, a 6-point rating scale

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients of either sex over the age of 18 years suffering from essential hypertension

requiring treatment according to the physician Exclusion Criteria:

- Hypersensitivity to the active component or to any of the excipients

- Pregnancy and lactation

- Biliary obstructive disorders

- Severe hepatic impairment

- Severe renal impairment

Locations and Contacts

Additional Information

Starting date: December 1999
Last updated: July 24, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017